I hope that improved data in half year from 2mg cohort(25 patients) in head and neck, and 2mg cohort(25 patients) in melanoma refractory or resistant to
anti-PD-1 could finally push the partnership deal through...
Idera is desperately for any partnership to survive, it is going to run out the money in a year...
In another trial, we reported 27.3% ORR in 22 patients
with head and neck cancer who were naïve to anti-PD-1 and received the
eight-milligram dose. The activity we've seen in this group was
encouraging because the second-line or later patients that we enrolled
in this study do progress very rapidly, often before we can even treat.
And the response rate that we observed was roughly double that reported
from monotherapy. We have now completed enrollment of 25 patients in the
two-milligram cohort in this study.
Finally, in melanoma patients refractory or resistant to
anti-PD-1, who received the eight-milligram dose, we reported a 20.7%
ORR in 29 patients; again, indicating SD-101 is providing benefit
significantly beyond monotherapy in this population. We are now
completing enrollment of 25 patients at two milligrams in this study. In
all three studies, adverse events related to SD-101 treatment were
transient mild to moderate flu-like symptoms.
More recently, we reported biomarker data analysis from
clinical trials of SD-101 in 3 tumor types. We demonstrated consistent
target engagement; induction of type 1 interferon response in the tumor
microenvironment; increases in recruitment of key cell types responsible
for tumor control; responses regardless of baseline PD-L1 status; and
importantly, that the trends in immune infiltrate changes between the
two-milligram and eight-milligram groups were entirely consistent with
the higher response rates in the two-milligram group.